<DOC>
	<DOCNO>NCT01571648</DOCNO>
	<brief_summary>The purpose study evaluate tolerability oral azacitidine treatment patient Myelodysplastic Syndromes ( MDS ) .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate Pharmacokinetics Tolerability Oral Azacitidine Japanese Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients must satisfy follow criterion enrol study : Have document diagnosis myelodysplastic syndrome ( MDS ) accord World Health Organization ( WHO ) 2008 classification Age â‰¥ 20 year ; Written inform consent ; Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ; Resolution toxic effect prior anticancer therapy ; Negative urine serum pregnancy test female childbearing potential . The presence follow exclude patient enrollment : Treatment chemotherapy , radiotherapy , surgery within 4 week study registration ; Pregnant breastfeeding female ; Previous concomitant malignancy MDS ; Significant active cardiac disease within previous 6 month ; Uncontrolled systemic infection Known infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>